Navigation Links
VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients
Date:10/14/2011

BROOMFIELD, Colo., Oct. 14, 2011 /PRNewswire/ -- Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes.   Patients who tested VeriStrat Good had significantly longer progression free survival (PFS) and overall survival (OS) when treated with the combination therapy as compared to patients who tested VeriStrat Poor.  

The study retrospectively, and in a fully blinded fashion, applied the VeriStrat test to a subset of the patient population from a Phase I/II clinical trial of erlotinib plus sunitinib in RCC patients.  VeriStrat analysis was performed on all available serum samples.   Thirty-seven of 46 patients were classified as either VeriStrat Good or VeriStrat Poor based on the VeriStrat algorithm developed for non-small cell lung cancer (NSCLC).

The analysis showed that VeriStrat Good patients had a significantly longer PFS and OS versus VeriStrat Poor patients (PFS: median 12.3 vs. 4.7 months, log-rank p=0.025 and OS: median 38.4 vs. 11.6 months, log-rank p=0.045).   There was a statistically significant correlation between VeriStrat classification and Heng prognostic criteria, but not MSKCC classification.   VeriStrat showed the potential to further refine current grouping of RCC patients, separating MSKCC intermediate patients into VeriStrat Good and VeriStrat Poor subgroups with statistically significantly different PFS (log-rank p = 0.030).

Heinrich Roder, D.Phil., Chief Technology Officer of Biodesix stated, "This data set shows that our test, VeriStrat, may be helpful in identifying specific and useful disease characteristics in RCC.   It is also exciting to see that our test is showing utility across multiple solid tumors.   Oncologists currently do not have a simple serum test that can be used across multiple tumor types.   We are continuously engaging in additional studies to further explore the full clinical utility of VeriStrat."

About VeriStrat
VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC.  The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors (EGFRIs).  Samples are processed in Biodesix' CLIA accredited laboratory and results are typically reported within 72 hours of sample shipment.  VeriStrat has been validated in clinical studies with over 1500 patients.  For more information on VeriStrat or to order VeriStrat, visit www.VeriStratSupport.com or call the VeriStrat Support Hotline at 1-866-432-5930.

About Biodesix
Biodesix is a personalized medicine company focused on the development of diagnostic products that inform treatment decisions and improve patient care.  The Company's goal is to give physicians more information about the patient and their disease; understanding the clinically meaningful information contained within each patient's molecular profile leads to better care and better outcomes.  The Company's unique approach is based on ProTS®, proprietary technology which exploits the power of mass spectrometry and enables the discovery of specific molecular profiles.  Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies.  For more information about Biodesix, please visit www.Biodesix.com.

Sutent® is a registered trademark of Pfizer Inc.
Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC, a member of the Astellas Pharma Global Development Inc. group of companies.

This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Biodesix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
2. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
3. Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011
4. Cumberland Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 3, 2011
5. Renessa® Treatment for Stress Incontinence: Three Year Clinical Results Presented
6. Quest Diagnostics to Release Third Quarter 2011 Financial Results
7. Southern Home Medical Achieves Strong Third Quarter Results
8. Phase 1 / 2 Clinical Trial Results of KRX-0401 (Perifosine) Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology
9. Ultra Clean to Announce Third Quarter Results
10. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
11. Amylin Pharmaceuticals to Webcast Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
Breaking Medicine News(10 mins):